0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Neurological Review |

Epilepsy and Cognitive Impairments in Alzheimer Disease FREE

Jorge J. Palop, PhD; Lennart Mucke, MD
[+] Author Affiliations

Author Affiliations:Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco.


Section Editor: David E. Pleasure, MD

More Author Information
Arch Neurol. 2009;66(4):435-440. doi:10.1001/archneurol.2009.15.
Text Size: A A A
Published online

Alzheimer disease (AD) is associated with cognitive decline and increased incidence of seizures. Seizure activity in AD has been widely interpreted as a secondary process resulting from advanced stages of neurodegeneration, perhaps in combination with other age-related factors. However, recent findings in animal models of AD have challenged this notion, raising the possibility that aberrant excitatory neuronal activity represents a primary upstream mechanism that may contribute to cognitive deficits in these models. The following observations suggest that such activity may play a similar role in humans with AD: (1) patients with sporadic AD have an increased incidence of seizures that appears to be independent of disease stage and highest in cases with early onset; (2) seizures are part of the natural history of many pedigrees with autosomal dominant early-onset AD, including those with mutations in presenilin-1, presenilin-2, or the amyloid precursor protein, or with duplications of wild-type amyloid precursor protein; (3) inheritance of the major known genetic risk factor for AD, apolipoprotein E4, is associated with subclinical epileptiform activity in carriers without dementia; and (4) some cases of episodic amnestic wandering and disorientation in AD are associated with epileptiform activity and can be prevented with antiepileptic drugs. Here we review recent experimental data demonstrating that high levels of β-amyloid in the brain can cause epileptiform activity and cognitive deficits in transgenic mouse models of AD. We conclude that β-amyloid peptides may contribute to cognitive decline in AD by eliciting similar aberrant neuronal activity in humans and discuss potential clinical and therapeutic implications of this hypothesis.

Figures in this Article

Alzheimer disease (AD) is associated with increased cerebral levels of β-amyloid (Aβ) peptides, which are derived from the larger amyloid precursor protein (APP) by proteolytic cleavage. The hippocampus and entorhinal cortex play key roles in learning and memory and are primary targets of functional and pathological alterations in AD. Alzheimer disease is also associated with an increased incidence of unprovoked seizures.13Although neurodegeneration and aging-related cofactors may contribute to the development of seizures in AD, recent data obtained in transgenic mice expressing human APP (hAPP) in neurons indicate that high levels of Aβ are sufficient to elicit epileptiform activity and seizures, even at early stages of the disease process and in the absence of overt neuronal loss.4Notably, experimental manipulations that prevent seizure activity in hAPP mice also prevented cognitive deficits in these models.5Confirmation of a causal relationship between Aβ-induced aberrant excitatory neuronal activity and cognitive decline in humans with AD would provide important insights into the pathogenesis of AD and could open new therapeutic avenues.

Obviously mice are not people, just as apples are not planets. Nonetheless, because apples and planets both have mass, falling apples allowed Newton to elucidate the forces underlying planetary movements. In a similar vein, mice and people share several characteristics that make mice reasonable models for exploring human diseases. Indeed, evolutionary pressures have preserved many processes across mammalian species. An example is spatial learning and memory, which are essential for any species that must return to its home after foraging for food. Humans with AD and hAPP transgenic mice both show navigational deficits that are closely related to impairments of the hippocampus and entorhinal cortex.6,7

Although mice never develop AD-like pathology spontaneously, the murine brain is similar enough to the human brain to develop many AD-like changes when exposed to high levels of human Aβ, including amyloid plaques, neuritic dystrophy, gliosis, synaptic deficits, and a range of cognitive and noncognitive behavioral alterations.5,817Notably, some alterations or associations were discovered in hAPP mice and subsequently identified for the first time in humans with AD, including loss of calbindin levels in the dentate gyrus10and the relation between transforming growth factor β and cerebral amyloid angiopathy.18

While none of the available singly transgenic models recapitulates the full spectrum of the human disease, they make it possible to dissect the complexity of AD and to assess the relative pathogenic impact of individual factors in vivo. Compound transgenic mice combining different factors suspected of pathogenic roles in AD or related conditions have shed light on synergisms between Aβ and apolipoprotein (apo) E4,19Aβ and tau,5,20and Aβ and α-synuclein.21We recently used hAPP mice to determine the effect of high Aβ levels on neural network activity and the dependence of this effect on tau.

The brain is characterized by multiple levels of complexity, ranging from molecules and individual synapses to circuits and interconnected networks. Activities in lower levels determine activities in higher levels and vice versa. Consequently, molecular and synaptic alterations can affect the function of networks and, in turn, alterations in network functions can affect individual synapses and molecules. It is well known that Aβ causes depression of excitatory neurotransmission at specific synaptic connections (Figure 1),4,8,2326but the net effect of Aβ on the activity of microcircuits and broader neural networks had been unknown.

Place holder to copy figure label and caption
Figure 1.

β-Amyloid (Aβ) can affect neuronal activity at multiple levels of complexity. High levels of Aβ depress excitatory synaptic transmission and impair synaptic plasticity at the level of specific synapses (A) but elicit epileptiform activity and seizures at the network level (B). Whether there is a causal relationship between these Aβ effects is unknown. F indicates frontal; fEPSP, field excitatory postsynaptic potentials; H, hippocampal; hAPPJ20, human amyloid precursor protein transgenic mice; L, left; NTG, nontransgenic mice; O, posterior-parietal; P, parietal; R, right; T, temporal; and TBS, θ-burst stimulation. Adapted from Neuron4and Nature.22

Graphic Jump Location

To shed light on this issue, we continually monitored neuronal activity in cortical and hippocampal networks by video electroencephalography (EEG) recordings in hAPP mice (J20 line; hAPPJ20), which have behavioral and synaptic deficits but no obvious neuronal loss.4These recordings revealed frequent epileptiform activity including spikes and sharp waves (Figure 1). The hAPPJ20 mice also had intermittent unprovoked seizures involving diverse regions of the neocortex and hippocampus that were not accompanied by tonic or clonic motor activity (Figure 1). These results suggest that high levels of Aβ are sufficient to elicit epileptiform activity in vivo in the absence of frank neurodegeneration. Therefore, aberrant network synchronization appears to be a primary effect of high Aβ levels rather than a secondary consequence of extensive neurodegeneration. Electroencephalographic epileptiform activity has subsequently been identified in independent transgenic mouse models of AD, including hAPPJ9/FYN mice (unpublished data), Tg2576 mice,27and hAPP/PS1 mice,28underlining the robustness of this Aβ effect.

Several lines of evidence suggest that Aβ-induced aberrant neuronal activity could contribute to cognitive deficits in hAPP mice and in AD. Epileptic activity triggers a variety of inhibitory compensatory responses in hippocampal circuits to counteract imbalances in network activity (Figure 2).4Although these compensatory inhibitory mechanisms may dampen aberrant increases in network activity, they may also interfere with normal neuronal and synaptic functions required for learning and memory.22In hAPP mice, Aβ-induced epileptic activity was associated with sprouting of inhibitory axonal terminals in the molecular layer of the dentate gyrus, enhanced synaptic inhibition, and alterations in several calcium- and activity-regulated proteins in granule cells including calbindin, Fos, and Arc (Figure 2B).4,10,1214Importantly, these alterations correlated tightly with each other and with deficits in learning and memory,10suggesting that Aβ-induced aberrant neuronal activity and associated compensatory inhibitory responses may be causally linked to cognitive decline (Figure 2A). We further assessed this possibility by crossing hAPP mice onto a tau-deficient (tau–/–) background, a genetic manipulation that blocks Aβ- and excitotoxin-induced overexcitation.4,5Reducing tau levels in hAPP mice prevented learning and memory deficits, compensatory inhibitory responses, premature mortality, and most evidence for aberrant network activity without affecting either hAPP or Aβ (Figure 3).4,5These results are consistent with our hypothesis that Aβ-induced aberrant neuronal activity contributes causally to learning and memory deficits in hAPP mice and possibly in AD.

Place holder to copy figure label and caption
Figure 2.

Our latest view of the β-amyloid (Aβ) cascade hypothesis and resultant hippocampal remodeling. A, High levels of Aβ induce epileptiform activity, which triggers compensatory inhibitory responses to counteract overexcitation. Both aberrant excitatory neuronal activity and compensatory inhibitory responses may contribute to Alzheimer disease–related cognitive deficits. B, Aβ-dependent circuit remodeling in the dentate gyrus of human amyloid precursor protein transgenic mice (hAPPJ20). In contrast to nontransgenic mice (NTG), hAPPJ20 mice show increased sprouting of inhibitory axonal terminals in the molecular layer, enhanced synaptic inhibition, ectopic neuropeptide Y (NPY) expression in granule cells, and depletion of activity-dependent proteins such as calbindin, Arc, and Fos. These alterations likely reflect compensatory inhibitory responses to aberrant excitatory neuronal activity. CB indicates calbindin; GABA, γ-aminobutyric acid; Glu, glutamate; PV, parvalbumin; and SOM, somatostatin. Adapted from Neuron.4

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Tau reduction prevents β-amyloid (Aβ) toxicity in vivo. Thioflavin-S staining (A) and anti-Aβ immunostaining (B) of hippocampal amyloid plaques in mice with human amyloid precursor protein transgenic mice (hAPPJ20) with 2 (tau+/+) or no (tau–/–) functional tau alleles revealed that tau reduction did not alter plaque loads in hAPP mice. However, tau reduction effectively prevented Aβ-induced depletion of calbindin (CB) (C) and increases in neuropeptide Y (NPY) (D) in the dentate gyrus as well as spatial memory deficits in the Morris water maze (E). The representative path tracings in (E) were obtained in a probe trial (platform removed) 24 hours after 3 days of hidden platform training. Tau reduction markedly increased focused search activity in the target quadrant (light gray) and over the platform location (dark gray), suggesting improved spatial memory retention. Adapted from Neuron4and Science.5

Graphic Jump Location

The incidence of unprovoked seizures is clearly higher in sporadic AD than in reference populations, and the increase appears to be independent of disease stage.2,2931However, just as in hAPP mice, frank convulsive seizures are rather infrequent in AD. Nonetheless, 7% to 21% of patients with sporadic AD are estimated to have at least 1 unprovoked clinically apparent seizure during their illness.2,2933The relative risk of unprovoked seizures markedly increases in patients with early-onset AD, reaching 3-, 20-, and 87-fold with dementia onset when aged 70-79, 60-69, or 50-59 years, respectively.2

The relationship between clinically apparent seizures and AD is even stronger in autosomal dominant early-onset AD, which can be caused by mutations in hAPP (≥23 mutations), presenilin-1 (≥174 mutations), or presenilin-2 (≥14 mutations) and by duplications of wild-type hAPP (≥7 duplications).34These genetic alterations either increase Aβ42 production or the Aβ42:Aβ40 ratio or promote Aβ aggregation, providing strong evidence for a causal role of Aβ in AD. Notably, more than 30 mutations in presenilin-1 are associated with epilepsy,35and 56% of patients with early-onset AD with APP duplications have seizures.3Around 83% of pedigrees with very early onset of dementia (<40 years of age) show frank seizures or epilepsy.1Most cases of Down syndrome have an extra copy of the hAPP gene and develop early-onset AD; notably, 84% of those cases also have frank seizures.36

These clinical observations are consistent with our experimental findings and with our hypothesis that Aβ is an important cause of aberrant neural network synchronization in AD.

Apolipoprotein is the most important known genetic risk factor for sporadic AD. Although the mechanisms underlying this link remain to be fully elucidated, much evidence suggests that ApoE4 contributes to AD pathogenesis through both Aβ-dependent and Aβ-independent pathways.19Aberrant increases in network excitability may represent a critical convergence point for the adverse effects of ApoE4 and Aβ in the pathogenesis of AD. In contrast to noncarriers, ApoE4 carriers without dementia showed signs of epileptiform activity and sharp waves on their EEGs after hyperventilation, although their EEGs were normal under resting conditions.37Similar changes have been found in subjects with high familial risk of developing AD, such as first-order relatives of patients with early-onset AD.38Apolipoprotein E4 also exacerbates epilepsy and promotes memory impairment in patients with long-standing intractable temporal lobe epilepsy.39These data indicate that major genetic risk factors for developing AD are associated with increased network excitability in individuals without dementia, suggesting that this type of network dysfunction might play an early role in the establishment of pathogenic cascades leading to AD.

Many patients with AD experience fluctuations in cognitive functions such as transient episodes of amnestic wandering and disorientation.22,40The intermittent inability to retrieve memories cannot be easily explained by relatively protracted processes such as neuronal loss, plaque deposition, or tangle formation. It seems more likely that abnormal neuronal network activity is to blame. Interestingly, amnestic episodes in patients with AD have been associated with epileptiform EEG discharges such as spikes and sharp waves.41What is more, these specific cognitive disturbances and the associated epileptiform EEG discharges could be prevented by antiepileptic treatment.41Epileptiform discharges in patients with temporal lobe epilepsy can also lead to transient amnesia and even simulate AD-like memory disturbances.42Therefore, nonconvulsive epileptiform activity could underlie at least some of the cognitive impairments observed in AD. Prospective clinical investigations focusing on hard-to-detect forms of epileptic activity are needed to further test this hypothesis in the clinic.

Many drugs for AD currently in clinical trials aim to reduce Aβ levels. However, the efficacy and long-term safety of these drugs have not yet been established. The studies discussed above suggest that reducing aberrant synchronization of neuronal activity may effectively protect the brain against Aβ's adverse effects on cognitive functions and thus could provide a complementary or alternative therapeutic strategy. We specifically hypothesize that cognitive deficits in hAPP mice, and perhaps in humans with AD, result from the combination of aberrant excitatory neuronal activity and of compensatory inhibitory responses that reduce overexcitation but end up constraining the functional agility of processes required for learning and memory (Figure 2A). Combination treatments may be required to block the contributions of overexcitation and overinhibition to AD-related cognitive deficits, although it seems reasonable to speculate that blocking the former should prevent, and might reverse, the latter.

Low doses of the γ-aminobutyric acid A (GABAA) receptor antagonist picrotoxin prevented long-term potentiation deficits in the dentate gyrus and cognitive impairments in hAPP/presenilin 1 mice43as well as in Ts65Dn mice, a mouse model of Down syndrome.44These results indicate that inhibition in the dentate gyrus may critically contribute to cognitive impairments in these overlapping disorders. However, blocking inhibition with GABAAreceptor antagonists can also exacerbate or precipitate seizures in hAPP mice,4,45making this therapeutic intervention risky, at least as a monotherapy. Blocking overexcitation might provide a more effective upstream approach. A key question is whether any of the available Food and Drug administration–approved antiepileptic drugs could prevent or ameliorate Aβ-induced aberrant network excitation. Notably, some of the most commonly used antiepileptic drugs actually worsened seizure activity in hAPPJ20 mice,46underlining the need to carefully evaluate these agents at the preclinical level before designing clinical trials for people with AD or mild cognitive impairment. Consistent with this notion, the few clinical trials of antiepileptic drugs that have been conducted in AD so far have yielded disappointing results, but they were small and focused mostly on behavioral abnormalities in late stages of the disease.47

Up to one-third of patients with seizures without AD do not respond satisfactorily to medication and develop refractory epilepsy.48Antiepileptic drugs can also aggravate or precipitate certain types of seizures.49Thus, the efficacy of antiepileptic drugs in AD will likely depend on the exact mechanisms of Aβ-induced dysrhythmias, which are currently unknown. Some antiepileptic drugs may elicit beneficial effects, whereas others may exacerbate aberrant network activity and cognitive decline. It is also possible that novel drugs may have to be developed to specifically block Aβ-induced dysrhythmias in AD. Our experimental data suggest that reducing tau levels is highly effective in preventing Aβ-induced network dysfunction and cognitive deficits in vivo (Figure 3).4,5However, much more research is needed to further assess the efficacy and safety of this novel therapeutic strategy.

Correspondence:Jorge J. Palop, PhD, or Lennart Mucke, MD, Gladstone Institute of Neurological Disease, San Francisco, CA 94158 (jpalop@gladstone.ucsf.eduor lmucke@gladstone.ucsf.edu).

Accepted for Publication:September 10, 2008.

Published Online:February 9, 2009 (doi:10.1001/archneurol.2009.15).

Author Contributions:Study concept and design: Palop and Mucke. Acquisition of data: Palop. Analysis and interpretation of data: Palop and Mucke. Drafting of the manuscript: Palop and Mucke. Critical revision of the manuscript for important intellectual content: Palop and Mucke. Obtained funding: Mucke. Administrative, technical, and material support: Palop and Mucke. Study supervision: Mucke.

Financial Disclosure:Dr Mucke reports being a consultant for Merck.

Funding/Support:This study was supported by grants NS041787 and AG023501 from the National Institutes of Health (Dr Mucke).

Snider  BJNorton  JCoats  MA  et al.  Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol 2005;62 (12) 1821- 1830
PubMed Link to Article
Amatniek  JCHauser  WADelCastillo-Castaneda  C  et al.  Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 2006;47 (5) 867- 872
PubMed Link to Article
Cabrejo  LGuyant-Maréchal  LLaquerriére  A  et al.  Phenotype associated with APP duplication in five families. Brain 2006;129 (pt 11) 2966- 2976
PubMed Link to Article
Palop  JJChin  JRoberson  ED  et al.  Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007;55 (5) 697- 711
PubMed Link to Article
Roberson  EDScearce-Levie  KPalop  JJ  et al.  Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 2007;316 (5825) 750- 754
PubMed Link to Article
deIpolyi  ARRankin  KPMucke  LMiller  BLGorno-Tempini  ML Spatial cognition and the human navigation network in AD and MCI. Neurology 2007;69 (10) 986- 997
PubMed Link to Article
Deipolyi  ARFang  SPalop  JJYu  G-QWang  XMucke  L Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Neurobiol Aging 2008;29 (2) 253- 266
PubMed Link to Article
Hsia  AYMasliah  EMcConlogue  L  et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A 1999;96 (6) 3228- 3233
PubMed Link to Article
Chapman  PFWhite  GLJones  MW  et al.  Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 1999;2 (3) 271- 276
PubMed Link to Article
Palop  JJJones  BKekonius  L  et al.  Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A 2003;100 (16) 9572- 9577
PubMed Link to Article
Kobayashi  DTChen  KS Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav 2005;4 (3) 173- 196
PubMed Link to Article
Palop  JJChin  JBien-Ly  N  et al.  Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice. J Neurosci 2005;25 (42) 9686- 9693
PubMed Link to Article
Chin  JPalop  JJPuoliväli  J  et al.  Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 2005;25 (42) 9694- 9703
PubMed Link to Article
Cheng  IHScearce-Levie  KLegleiter  J  et al.  Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 2007;282 (33) 23818- 23828
PubMed Link to Article
Meilandt  WJYu  G-QChin  J  et al.  Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 2008;28 (19) 5007- 5017
PubMed Link to Article
Janus  CWestaway  D Transgenic mouse models of Alzheimer's disease. Physiol Behav 2001;73 (5) 873- 886
PubMed Link to Article
Götz  JIttner  LM Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 2008;9 (7) 532- 544
PubMed Link to Article
Wyss-Coray  TMasliah  EMallory  M  et al.  Amyloidogenic role of cytokine TGF-β1 in transgenic mice and Alzheimer's disease. Nature 1997;389 (6651) 603- 606
PubMed Link to Article
Mahley  RWWeisgraber  KHHuang  Y Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 2006;103 (15) 5644- 5651
PubMed Link to Article
Lewis  JDickson  DWLin  WL  et al.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001;293 (5534) 1487- 1491
PubMed Link to Article
Masliah  ERockenstein  EVeinbergs  I  et al.  β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 2001;98 (21) 12245- 12250
PubMed Link to Article
Palop  JJChin  JMucke  L A network dysfunction perspective on neurodegenerative diseases. Nature 2006;443 (7113) 768- 773
PubMed Link to Article
Walsh  DMKlyubin  IFadeeva  JV  et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416 (6880) 535- 539
PubMed Link to Article
Kamenetz  FTomita  THsieh  H  et al.  APP processing and synaptic function. Neuron 2003;37 (6) 925- 937
PubMed Link to Article
Hsieh  HBoehm  JSato  C  et al.  AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron 2006;52 (5) 831- 843
PubMed Link to Article
Shankar  GMBloodgood  BLTownsend  MWalsh  DMSelkoe  DJSabatini  BL Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007;27 (11) 2866- 2875
PubMed Link to Article
Chin  JLing  H-PComery  T  et al.  Chronic imbalance in neuronal activity and compensatory plasticity are associated with cognitive impairment in Tg2576 and PS1/APP mouse models of Alzheimer’s disease.  Presented at: the International Conference on Alzheimer’s Disease 2008 July 27, 2008 Chicago, IL
Tanila  JMinkeviciene  RDobszay  MB  et al.  Fibrillar beta-amyloid associates with epileptic seizures in APPswe/PS1de9 mice and changes excitability in cortical and hippocampal neurons.  Presented at: the Society for Neuroscience Annual Meeting 2008 Nov 18, 2008 Washington, DC
Hauser  WAMorris  MLHeston  LLAnderson  VE Seizures and myoclonus in patients with Alzheimer's disease. Neurology 1986;36 (9) 1226- 1230
PubMed Link to Article
Romanelli  MFMorris  JCAshkin  KCoben  LA Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch Neurol 1990;47 (8) 847- 850
PubMed Link to Article
Mendez  MLim  G Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging 2003;20 (11) 791- 803
PubMed Link to Article
Mendez  MFCatanzaro  PDoss  RCARguello  RFrey  WH  II Seizures in Alzheimer's disease: clinicopathologic study. J Geriatr Psychiatry Neurol 1994;7 (4) 230- 233
PubMed Link to Article
Volicer  LSmith  SVolicer  BJ Effect of seizures on progression of dementia of the Alzheimer type. Dementia 1995;6 (5) 258- 263
PubMed
 The Alzheimer disease and frontotemporal dementia mutation database. Flanders Interuniversity Institute for Biotechnology Department of Molecular Genetics Web site http://www.molgen.ua.ac.be. Accessed September 6, 2008
Larner  AJDoran  M Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol 2006;253 (2) 139- 158
PubMed Link to Article
Lai  FWilliams  RS A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989;46 (8) 849- 853
PubMed Link to Article
Ponomareva  NVKorovaitseva  GIRogaev  EI EEG alterations in non-demented individuals related to apolipoprotein E genotype and to risk of Alzheimer disease. Neurobiol Aging 2008;29 (6) 819- 827
PubMed Link to Article
Ponomareva  NVSelesneva  NDJarikov  GA EEG alterations in subjects at high familial risk for Alzheimer's disease. Neuropsychobiology 2003;48 (3) 152- 159
PubMed Link to Article
Busch  RMLineweaver  TTNaugle  RI  et al.  ApoE-epsilon4 is associated with reduced memory in long-standing intractable temporal lobe epilepsy. Neurology 2007;68 (6) 409- 414
PubMed Link to Article
Bradshaw  JSaling  MHopwood  MAnderson  VBrodtmann  A Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct. J Neurol Neurosurg Psychiatry 2004;75 (3) 382- 387
PubMed Link to Article
Rabinowicz  ALStarkstein  SELeiguarda  RCColeman  AE Transient epileptic amnesia in dementia: a treatable unrecognized cause of episodic amnestic wandering. Alzheimer Dis Assoc Disord 2000;14 (4) 231- 233
PubMed Link to Article
Sinforiani  EManni  RBernasconi  LBanchieri  LMZucchella  C Memory disturbances and temporal lobe epilepsy simulating Alzheimer's disease: a case report. Funct Neurol 2003;18 (1) 39- 41
PubMed
Yoshiike  YKimura  TYamashita  S  et al.  GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS ONE 2008;3 (8) e3029
PubMed Link to Article
Fernandez  FMorishita  WZuniga  E  et al.  Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 2007;10 (4) 411- 413
PubMed
Del Vecchio  RAGold  LHNovick  SJWong  GHyde  LA Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci Lett 2004;367 (2) 164- 167
PubMed Link to Article
Palop  JJThwin  MTHo  K  et al.  Alterations in voltage-gated sodium channels of transgenic mouse models of Alzheimer’s disease: implications for Aβ-induced network dysfunction.  Presented at: the International Conference of Alzheimer’s Disease 2008 July 27, 2008 Chicago, IL
Herrmann  NLanctot  KLRothenburg  LSEryavec  G A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;23 (2) 116- 119
PubMed Link to Article
French  JA Refractory epilepsy: clinical overview. Epilepsia 2007;48 ((suppl 1)) 3- 7
PubMed Link to Article
Thomas  PValton  LGenton  P Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 2006;129 (Pt 5) 1281- 1292
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

β-Amyloid (Aβ) can affect neuronal activity at multiple levels of complexity. High levels of Aβ depress excitatory synaptic transmission and impair synaptic plasticity at the level of specific synapses (A) but elicit epileptiform activity and seizures at the network level (B). Whether there is a causal relationship between these Aβ effects is unknown. F indicates frontal; fEPSP, field excitatory postsynaptic potentials; H, hippocampal; hAPPJ20, human amyloid precursor protein transgenic mice; L, left; NTG, nontransgenic mice; O, posterior-parietal; P, parietal; R, right; T, temporal; and TBS, θ-burst stimulation. Adapted from Neuron4and Nature.22

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Our latest view of the β-amyloid (Aβ) cascade hypothesis and resultant hippocampal remodeling. A, High levels of Aβ induce epileptiform activity, which triggers compensatory inhibitory responses to counteract overexcitation. Both aberrant excitatory neuronal activity and compensatory inhibitory responses may contribute to Alzheimer disease–related cognitive deficits. B, Aβ-dependent circuit remodeling in the dentate gyrus of human amyloid precursor protein transgenic mice (hAPPJ20). In contrast to nontransgenic mice (NTG), hAPPJ20 mice show increased sprouting of inhibitory axonal terminals in the molecular layer, enhanced synaptic inhibition, ectopic neuropeptide Y (NPY) expression in granule cells, and depletion of activity-dependent proteins such as calbindin, Arc, and Fos. These alterations likely reflect compensatory inhibitory responses to aberrant excitatory neuronal activity. CB indicates calbindin; GABA, γ-aminobutyric acid; Glu, glutamate; PV, parvalbumin; and SOM, somatostatin. Adapted from Neuron.4

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Tau reduction prevents β-amyloid (Aβ) toxicity in vivo. Thioflavin-S staining (A) and anti-Aβ immunostaining (B) of hippocampal amyloid plaques in mice with human amyloid precursor protein transgenic mice (hAPPJ20) with 2 (tau+/+) or no (tau–/–) functional tau alleles revealed that tau reduction did not alter plaque loads in hAPP mice. However, tau reduction effectively prevented Aβ-induced depletion of calbindin (CB) (C) and increases in neuropeptide Y (NPY) (D) in the dentate gyrus as well as spatial memory deficits in the Morris water maze (E). The representative path tracings in (E) were obtained in a probe trial (platform removed) 24 hours after 3 days of hidden platform training. Tau reduction markedly increased focused search activity in the target quadrant (light gray) and over the platform location (dark gray), suggesting improved spatial memory retention. Adapted from Neuron4and Science.5

Graphic Jump Location

Tables

References

Snider  BJNorton  JCoats  MA  et al.  Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol 2005;62 (12) 1821- 1830
PubMed Link to Article
Amatniek  JCHauser  WADelCastillo-Castaneda  C  et al.  Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 2006;47 (5) 867- 872
PubMed Link to Article
Cabrejo  LGuyant-Maréchal  LLaquerriére  A  et al.  Phenotype associated with APP duplication in five families. Brain 2006;129 (pt 11) 2966- 2976
PubMed Link to Article
Palop  JJChin  JRoberson  ED  et al.  Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007;55 (5) 697- 711
PubMed Link to Article
Roberson  EDScearce-Levie  KPalop  JJ  et al.  Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 2007;316 (5825) 750- 754
PubMed Link to Article
deIpolyi  ARRankin  KPMucke  LMiller  BLGorno-Tempini  ML Spatial cognition and the human navigation network in AD and MCI. Neurology 2007;69 (10) 986- 997
PubMed Link to Article
Deipolyi  ARFang  SPalop  JJYu  G-QWang  XMucke  L Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Neurobiol Aging 2008;29 (2) 253- 266
PubMed Link to Article
Hsia  AYMasliah  EMcConlogue  L  et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A 1999;96 (6) 3228- 3233
PubMed Link to Article
Chapman  PFWhite  GLJones  MW  et al.  Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 1999;2 (3) 271- 276
PubMed Link to Article
Palop  JJJones  BKekonius  L  et al.  Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A 2003;100 (16) 9572- 9577
PubMed Link to Article
Kobayashi  DTChen  KS Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav 2005;4 (3) 173- 196
PubMed Link to Article
Palop  JJChin  JBien-Ly  N  et al.  Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice. J Neurosci 2005;25 (42) 9686- 9693
PubMed Link to Article
Chin  JPalop  JJPuoliväli  J  et al.  Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 2005;25 (42) 9694- 9703
PubMed Link to Article
Cheng  IHScearce-Levie  KLegleiter  J  et al.  Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 2007;282 (33) 23818- 23828
PubMed Link to Article
Meilandt  WJYu  G-QChin  J  et al.  Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 2008;28 (19) 5007- 5017
PubMed Link to Article
Janus  CWestaway  D Transgenic mouse models of Alzheimer's disease. Physiol Behav 2001;73 (5) 873- 886
PubMed Link to Article
Götz  JIttner  LM Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 2008;9 (7) 532- 544
PubMed Link to Article
Wyss-Coray  TMasliah  EMallory  M  et al.  Amyloidogenic role of cytokine TGF-β1 in transgenic mice and Alzheimer's disease. Nature 1997;389 (6651) 603- 606
PubMed Link to Article
Mahley  RWWeisgraber  KHHuang  Y Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 2006;103 (15) 5644- 5651
PubMed Link to Article
Lewis  JDickson  DWLin  WL  et al.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001;293 (5534) 1487- 1491
PubMed Link to Article
Masliah  ERockenstein  EVeinbergs  I  et al.  β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 2001;98 (21) 12245- 12250
PubMed Link to Article
Palop  JJChin  JMucke  L A network dysfunction perspective on neurodegenerative diseases. Nature 2006;443 (7113) 768- 773
PubMed Link to Article
Walsh  DMKlyubin  IFadeeva  JV  et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416 (6880) 535- 539
PubMed Link to Article
Kamenetz  FTomita  THsieh  H  et al.  APP processing and synaptic function. Neuron 2003;37 (6) 925- 937
PubMed Link to Article
Hsieh  HBoehm  JSato  C  et al.  AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron 2006;52 (5) 831- 843
PubMed Link to Article
Shankar  GMBloodgood  BLTownsend  MWalsh  DMSelkoe  DJSabatini  BL Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007;27 (11) 2866- 2875
PubMed Link to Article
Chin  JLing  H-PComery  T  et al.  Chronic imbalance in neuronal activity and compensatory plasticity are associated with cognitive impairment in Tg2576 and PS1/APP mouse models of Alzheimer’s disease.  Presented at: the International Conference on Alzheimer’s Disease 2008 July 27, 2008 Chicago, IL
Tanila  JMinkeviciene  RDobszay  MB  et al.  Fibrillar beta-amyloid associates with epileptic seizures in APPswe/PS1de9 mice and changes excitability in cortical and hippocampal neurons.  Presented at: the Society for Neuroscience Annual Meeting 2008 Nov 18, 2008 Washington, DC
Hauser  WAMorris  MLHeston  LLAnderson  VE Seizures and myoclonus in patients with Alzheimer's disease. Neurology 1986;36 (9) 1226- 1230
PubMed Link to Article
Romanelli  MFMorris  JCAshkin  KCoben  LA Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch Neurol 1990;47 (8) 847- 850
PubMed Link to Article
Mendez  MLim  G Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging 2003;20 (11) 791- 803
PubMed Link to Article
Mendez  MFCatanzaro  PDoss  RCARguello  RFrey  WH  II Seizures in Alzheimer's disease: clinicopathologic study. J Geriatr Psychiatry Neurol 1994;7 (4) 230- 233
PubMed Link to Article
Volicer  LSmith  SVolicer  BJ Effect of seizures on progression of dementia of the Alzheimer type. Dementia 1995;6 (5) 258- 263
PubMed
 The Alzheimer disease and frontotemporal dementia mutation database. Flanders Interuniversity Institute for Biotechnology Department of Molecular Genetics Web site http://www.molgen.ua.ac.be. Accessed September 6, 2008
Larner  AJDoran  M Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol 2006;253 (2) 139- 158
PubMed Link to Article
Lai  FWilliams  RS A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989;46 (8) 849- 853
PubMed Link to Article
Ponomareva  NVKorovaitseva  GIRogaev  EI EEG alterations in non-demented individuals related to apolipoprotein E genotype and to risk of Alzheimer disease. Neurobiol Aging 2008;29 (6) 819- 827
PubMed Link to Article
Ponomareva  NVSelesneva  NDJarikov  GA EEG alterations in subjects at high familial risk for Alzheimer's disease. Neuropsychobiology 2003;48 (3) 152- 159
PubMed Link to Article
Busch  RMLineweaver  TTNaugle  RI  et al.  ApoE-epsilon4 is associated with reduced memory in long-standing intractable temporal lobe epilepsy. Neurology 2007;68 (6) 409- 414
PubMed Link to Article
Bradshaw  JSaling  MHopwood  MAnderson  VBrodtmann  A Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct. J Neurol Neurosurg Psychiatry 2004;75 (3) 382- 387
PubMed Link to Article
Rabinowicz  ALStarkstein  SELeiguarda  RCColeman  AE Transient epileptic amnesia in dementia: a treatable unrecognized cause of episodic amnestic wandering. Alzheimer Dis Assoc Disord 2000;14 (4) 231- 233
PubMed Link to Article
Sinforiani  EManni  RBernasconi  LBanchieri  LMZucchella  C Memory disturbances and temporal lobe epilepsy simulating Alzheimer's disease: a case report. Funct Neurol 2003;18 (1) 39- 41
PubMed
Yoshiike  YKimura  TYamashita  S  et al.  GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS ONE 2008;3 (8) e3029
PubMed Link to Article
Fernandez  FMorishita  WZuniga  E  et al.  Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 2007;10 (4) 411- 413
PubMed
Del Vecchio  RAGold  LHNovick  SJWong  GHyde  LA Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci Lett 2004;367 (2) 164- 167
PubMed Link to Article
Palop  JJThwin  MTHo  K  et al.  Alterations in voltage-gated sodium channels of transgenic mouse models of Alzheimer’s disease: implications for Aβ-induced network dysfunction.  Presented at: the International Conference of Alzheimer’s Disease 2008 July 27, 2008 Chicago, IL
Herrmann  NLanctot  KLRothenburg  LSEryavec  G A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;23 (2) 116- 119
PubMed Link to Article
French  JA Refractory epilepsy: clinical overview. Epilepsia 2007;48 ((suppl 1)) 3- 7
PubMed Link to Article
Thomas  PValton  LGenton  P Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 2006;129 (Pt 5) 1281- 1292
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

5,803 Views
219 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
Jobs